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Custom-fit ruthenium(II) metallopeptides:  
A new twist to DNA binding with coordination compounds  
 Ilaria Gamba,[b],∆ Iria Salvadó,[a],∆ Gustavo Rama,[b],∆ Miriam Bertazzon,[a] Mateo I. Sánchez,[a] 
Víctor M. Sánchez-Pedregal,[a] José Martínez-Costas,[c] Rosa F. Brissos,[d] Patrick Gamez,[d] José L. 
Mascareñas,[a] Miguel Vázquez López[b],* and M. Eugenio Vázquez[a],* 
 
Abstract: A new bipyridine building 
block has been used for the solid-phase 
synthesis of dinuclear DNA-binding 
ruthenium(II) metallopeptides. Detailed 
spectroscopic studies suggest that these 
compounds bind to the DNA by 
insertion into the DNA minor groove. 
Moreover, the potential of the solid-
phase peptide synthesis approach is 
demonstrated by the straightforward 
synthesis of an octaarginine derivative 
that shows effective cellular 
internalization and cytotoxicity linked 
with strong DNA interaction, as 
evidenced by steady-state fluorescence 
spectroscopy and AFM studies.  
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Mapping the human genome has provided a wealth of information 
and potential DNA targets of both therapeutic and diagnostic 
relevance that has stimulated the search for new DNA binding 
agents.1 In addition to the extensive development of small organic 
binders, the past few years have witnessed an increased interest on 
the application of coordination compounds as DNA-targeted probes, 
reactive agents and therapeutics.2,3,4 Among them, ruthenium(II) 
polypyridyl mononuclear complexes have been exhaustively studied 
for their kinetic stability and convenient redox and optical 
properties.5,6 ,7  Surprisingly, dinuclear ruthenium (II) derivatives, 
despite systematically displaying better DNA-binding properties 
than their mononuclear counterparts,8 have scarcely been studied to 
date, 9 , 10 , 11 , 12  hampered by the stiff synthetic methodologies 
commonly used in the assembly of polypyridyl chelators that 
severely limit the structural modifications that can be efficiently 
accessed.13 Given our experience in the study of DNA recognition 
agents, particularly minor groove binders,14 and metallopeptides,15 
we sought to fill this gap with the development of custom-fit 
dinuclear ruthenium (II) metallopeptides, which could potentially 
combine the unique photophysical properties of the Ru(II) 
polypyridyl complexes with the synthetic versatility of solid-phase 
peptide synthesis methods that would allow the straightforward 
modification of the bis-chelating ligand for the modulation of the 
biophysical properties of the resulting complexes.16 To this end, we 
reasoned that appropriate derivatization of the widely used 2,2’-
bipyridine chelator in the form of a Fmoc-protected amino acid, 
might allow the straightforward solid-phase synthesis of 
metallopeptide precursor ligands, which could be easily tweaked in 
order to efficiently optimize the DNA-binding and biological 
properties of their resulting ruthenium(II) metallopeptides. 
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Results and Discussion 
Metallopeptide design and synthesis. Based on previous reports 
studying related bipyridine amino acids,17 we chose the Fmoc–βAla-
Bpy–OH dipeptide (1, Scheme 1) as the basic building block of our 
bis-chelating peptidic ligands. Following the synthesis of 1 using 
known procedures (supplementary information),15 we designed two 
simple peptide ligands containing two βAla-Bpy coordinating units 
in tandem (Ac–βAla-Bpy–βAla-Bpy–NH2), or separated by a short 
glycine residue linker (Ac–βAla-Bpy–Gly–βAla-Bpy–NH2), as 
simple test cases to demonstrate the flexibility of the SPPS 
methodology for the straightforward structural variation of the 
peptidic ligands. The peptides were synthesized following standard 
Fmoc/tBu solid-phase protocols.18 Once fully assembled—and while 
still attached to the solid support—the peptides were coordinated 
with the enantiopure Hua and von Zelewsky’s Λ-cis-
[Ru(Bpy)2(py)2]2+, or Δ-cis-[Ru(Bpy)2(py)2]2+ reagents,19 to give the 
desired ΛΛ– or ΔΔ–Ru2 and ΛΛ– or ΔΔ–Ru2Gly dinuclear 
complexes attached to the solid support (Scheme 1). Acidic cleavage, 
followed by reverse-phase HPLC purification, afforded the desired 
Ru(II) metallopeptides. It should be highlighted that the formation 
of the complexes in the solid phase from bis-bipyridine Ru(II) 
reagents outperforms widely used solution procedures,20 allowing 
the use of greater excess of metal precursors and simplifying the 
subsequent purification steps.21 To our knowledge, these species 
represent the first reported examples of dinuclear Ru(II) 
metallopeptides.22 
 
Scheme 1. Solid-Phase Peptide Synthesis of the model ΛΛ– and ΔΔ–Ru2 dinuclear 
complexes. ΛΛ– and ΔΔ–Ru2Gly are synthesized following the same procedure. 
DNA binding studies. The basic DNA binding properties of the 
ΛΛ– and ΔΔ–Ru2 dinuclear complexes were initially assessed by 
displacement experiments with ethidium bromide.23 Additionally, 
emission-quenching experiments showed that both ΛΛ– and ΔΔ–
Ru2 were effectively protected from luminescence deactivation with 
[Fe(CN)6]4– in the presence of calf thymus DNA (ctDNA).24 Thus, 
the ratio of the slopes in the absence and in presence of ctDNA, 
which is used as a measure of the protection of DNA-bound 
complexes against the dynamic quenching by the [Fe(CN)6]4–, 
resulting from electrostatic repulsion of the highly anionic 
ferricyanide from the polyanionic DNA, is 12.1 for ΛΛ–Ru2 and 7.3 
for ΔΔ–Ru2. These values are in the same range of those observed 
for other Ru(II) complexes that interact with the DNA (Supporting 
information, Figure S2). These preliminary experiments showed that, 
in contrast to the mononuclear tris-bipyridyl complex,25 both ΛΛ– 
and ΔΔ–Ru2 display significant DNA binding affinities (see 
supporting information, Figure S1). Encouraged by these results, we 
decided to exploit the intrinsic emission of the Ru(II) 
metallopeptides and their environment-sensitive luminescence for 
studying their interaction with synthetic oligonucleotides, 26 which 
would allow us to obtain quantitative information about their 
binding affinity towards particular DNA sequences. Thus, addition 
of successive aliquots of a stock oligonucleotide solution to 1 µM 
solutions of ΛΛ– or ΔΔ–Ru2 in Tris-HCl buffer resulted in a 
progressive increase in the emission intensity of the Ru(II) 
complexes, which was fitted to a binding model corresponding to 
the formation of specific ΛΛ– and ΔΔ–Ru2/dsDNA complexes 
(Figure 1).  
 
Figure 1. Left: (a) Luminescence spectra of 1 µM solutions of ΛΛ–Ru2 or ΔΔ–Ru2 in 
20 mM Tris-HCl buffer, 100 mM NaCl, pH 7.5; (b) ΛΛ–Ru2 in the presence of 20 µM 
of the GGCC hairpin oligonucleotide; (c, solid line) ΛΛ–Ru2 in the presence of 21 µM 
of the AAAATTT hairpin oligo; (c, dashed line) ΔΔ–Ru2 in the presence of 21 µM of 
the AAAATTT hairpin oligo. Right: Titration profiles of 1 µM ΛΛ–Ru2 with 
AAAATTT (▲); AAT (●); AAGCTT (○), and GGCC (△) oligonucleotides. Lines 
represent the best fit to a 1:1 binding model. Hairpin DNA oligonucleotide sequences, 
AAAATTT: 5’– GGC AAAATTT CGTTTTTCG AAATTTT GCC –3’; AAT: 5’– GGCG 
AAT GCAGCTTTTTGCTGC ATT CGCC –3’; AAGCTT: 5’– GGC AAGCTT 
CGCTTTTTGCG AAGCTT GCC –3’; GGCC: 5’– GGCAGGCCCAGC TTTTT 
GCTGGGCCTGCC –3’. 
The resulting apparent dissociation constants were strongly 
dependent on the oligonucleotide sequences, so that the lower 
apparent dissociation constants—as well as larger increases in the 
emission intensity—were observed for the A/T-rich oligonucleotides, 
while G/C-containing oligos only induced a modest increase in 
emission intensity and showed weaker apparent binding (Table 1). 
Moreover, ΛΛ–Ru2 consistently displayed stronger DNA binding 
affinities than its enantiomeric ΔΔ–Ru2 counterpart; this preferential 
DNA binding of the ΛΛ– enantiomer is consistent with earlier 
reports of chiral discrimination in homochiral dinuclear Ru(II) 
complexes, for which a preference of the ΛΛ–isomers for DNA 
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binding was also observed.27 In addition to the increased DNA 
affinity observed for the ΛΛ–Ru2 metallopeptide, its luminescence 
intensity in the presence of a high-affinity binding sequence 
(AAATTT) was much higher than that of the ΔΔ–Ru2 complex 
(Figure 1c, solid and dashed lines, respectively), and centered at a 
much shorter emission wavelength, hence suggesting a larger 
change in its immediate environment upon binding. This 
observation, together with the binding preference for A/T-rich 
sequences, would be consistent with a deeper insertion mechanism 
of this complex into the DNA minor groove.  
Titrations with the ΛΛ– and ΔΔ–Ru2Gly dinuclear metallopeptides 
showed similar tendencies to those of their homologous complexes 
lacking the Gly linker. Thus, the ΛΛ–Ru2Gly isomer displayed 
better apparent binding constants than ΔΔ–Ru2Gly, and both 
showed a clear preference for binding to extended A/T-rich 
oligonucleotides. Curiously, the glycine linker had subtle effects on 
the binding of these dinuclear metallopeptides, and while it had a 
slightly negative effect on the DNA binding of the ΛΛ–Ru2Gly 
isomer compared to the model ΛΛ–Ru2 (KD[AAATTT] ≈ 8.2 and 
5.8 µM, respectively), it induced an opposite, slightly favorable 
effect, on the DNA binding of the ΔΔ–Ru2Gly stereoisomer in 
comparison with the ΔΔ–Ru2 model compound (KD[AAATTT] ≈ 31 
and 14 µM, respectively), which again suggests some differences in 
the DNA binding modes of the isomeric complexes. As expected, no 
measurable binding was detected in control experiments with single-
stranded DNA oligonucleotides. Circular Dichroism experiments 
show an induced CD band at 320 nm by the ΛΛ–Ru2 isomer 
(supporting information, Figure S4a), which has been also reported 
for other Ru(II) complexes,28 but more importantly they show that 
the shape of the CD signals between 200 and 300 nm, corresponding 
to the DNA, are not significantly perturbed, thus indicating the 
retention of the B-DNA conformation.29 
Table 1. Dissociation constants of dinuclear ΛΛ–, ΔΔ–Ru2 and ΛΛ–, ΔΔ–Ru2Gly with 
selected oligonucleotides.  
Oligo[a] ΔΔ–Ru2[b] ΛΛ–Ru2 ΔΔ–Ru2Gly ΛΛ–Ru2Gly 
AAAATTT 31.0 (7.0) 5.8 (0.7) 13.9 (2.5) 8.2 (1.8) 
AAT 24.5 (3.5) 12.0 (0.6) 15.2 (2.6) 11.6 (1.6) 
AAGCTT 27.0 (6.0) 13.8 (0.7) 22.9 (6.8) 13.5 (2.2) 
GGCC > 50 15.5 (3.0) > 50 > 50 
KD (µM) were measured in 20 mM Tris-HCl buffer, 100 mM NaCl, pH 7.5 at 298 K. [a] 
Hairpin oligonucleotide binding sites; [b] Best fit according to a 1:1 model obtained for 
three independent titrations. The estimated KD error is shown between brackets. 
Saturation Transfer Difference (STD) NMR experiments also 
support the binding to the DNA.30 Thus, in the presence of ctDNA 
both enantiomers, ΛΛ– and ΔΔ–Ru2, give rise to STD signals in the 
region of 7.0-8.5 ppm of their spectra (Figure 2d, 2e), as expected 
for molecules that reversibly bind to the macromolecular receptor in 
the fast exchange regime; these resonances are not found in the 
control STD spectrum in the absence of ctDNA (Figure 2b). Both 
the ΛΛ– and ΔΔ–Ru2 enantiomers gave similar intensities in the 
STD experiments, in agreement with the similar values of their 
apparent binding affinities.  
 
Figure 2. STD NMR spectra (600 MHz, H2O, 25 ºC) of ΛΛ– and ΔΔ–Ru2 with calf-
thymus DNA. (a) Reference (off-resonance) 1H NMR spectrum of  150 µM ΔΔ–Ru2; 
(b) STD NMR of 150 µM ΔΔ–Ru2; (c) Reference (off-resonance) 1H NMR spectrum of 
a mixture of 150 µM of ΔΔ–Ru2 with 150 µM calf-thymus DNA; (d) STD NMR 
spectrum of the same sample in (c); (e) STD NMR of a mixture of 228 µM ΛΛ–Ru2 
and 250 µM calf-thymus DNA. Saturation time was 2 s at frequencies –40 ppm 
(reference, off-resonance spectra) and +4.0 ppm (STD, on-resonance spectra). 
Structural modification of the basic metallopeptide core: 
introduction of an octaarginine peptide tail. Given the relatively 
good DNA binding properties as well as the favorable luminescent 
emission displayed by the dinuclear ruthenium complexes, we were 
interested in studying their effect in living cells, but unfortunately 
these compounds were not internalized in Vero cells at 
concentrations of 5 or 25 µM and during variable incubations times 
(30 min and 1 h). Considering the effective cellular uptake induced 
by a number of cationic peptides, 31  and oligoarginines in 
particular,32 we decided to take advantage of the flexibility afforded 
by the SPPS methodology to synthesize an octaarginine-diruthenium 
derivative (Ru2–R8). This oligocationic metallopeptide was obtained 
following the same basic synthetic procedure outlined earlier, with 
the difference that the two βAla-Bpy-coordinating building blocks 
were appended at the N-terminus of a previously synthesized 
octaarginine peptide (Scheme 2). Unfortunately, attempts to prepare 
ΛΛ–Ru2–R8 or ΔΔ–Ru2–R8 in the solid support were unsuccessful, 
because the high temperatures required for the coordination of the 
relatively unreactive chiral Hua and von Zelewsky’s Λ-cis-
[Ru(Bpy)2(py)2]2+, or Δ-cis-[Ru(Bpy)2(py)2]2+ reagents resulted in a 
complex mixture of peptide degradation products. Fortunately, the 
achiral [Ru(Bpy)2(Cl)2] precursor complex required lower reaction 
temperatures, and allowed the synthesis of the Ru2–R8 dinuclear 
complex as a diasteromeric mixture.33 
Fluorescence titrations showed that the resulting octaarginine-
dinuclear Ru(II) metallopeptide Ru2–R8 displayed the same A/T-
rich sequence preference presented by the core ΛΛ– and ΔΔ–Ru2 
complexes. Moreover, the observed binding affinity for A/T-rich 
sequences was increased by this modification; probably because of 
the increased charge density of the oligocationic Ru2–R8 complex, 
which presumably would favorably contribute to the electrostatic 
component of the interaction with the negatively-charged DNA 
phosphate backbone. As expected, Ru2–R8 did not show any 
significant affinity for G/C-rich oligonucleotides. Moreover, the 
titration curve for the G/C-rich hairpin exhibited a rather complex 
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multiphasic profile (see supporting information), consistent with the 
formation of multiple low-affinity and nonspecific complexes 
resulting from electrostatic interactions between the polyanionic 
DNA and the highly charged conjugate.34  
 
Scheme 2. Solid-Phase Peptide Synthesis (SPPS) of the octaarginine Ru2–R8 dinuclear 
complex. 
AFM studies of the DNA binding. The interaction of the Ru(II) 
compounds ΔΔ–Ru2 and Ru2–R8 with DNA was further 
investigated with Atomic-Force Microscopy (AFM). To carry out 
these experiments, relaxed plasmid pBR322 DNA was used, as it 
would allow us to directly observe any potential interactions with 
metal complexes.35 As evidenced in Figure 3a, the relaxed DNA 
molecules distributed over the mica surface mostly exhibit open 
(circular) structures with some crossing points (see light-red arrow 
in Figure 3a), which illustrate the initiation of supercoiling. The 
incubation of ΔΔ–Ru2 with the relaxed plasmid for 24 hours clearly 
resulted in the alteration of the initial morphology of the DNA 
structure (Figure 4b); indeed, significantly more crossing points 
were observed and the formation of supercoiled forms was obvious 
(see light-blue arrows in Figure 3b). Moreover, large open forms 
such as those observed in Figure 3a were not present anymore. 
These features are indicative of strong interactions of ΔΔ–Ru2 with 
relaxed pBR322 DNA. Incubation with Ru2–R8 revealed a higher 
affinity of the ruthenium compound (compared to ΔΔ–Ru2) for 
DNA (Figure 3c); actually, the supercoiled forms of DNA were 
present in major proportion (in fact the supercoiled forms were 
visibly longer than those observed with ΔΔ–Ru2; see light-green 
arrows in Figure 3c). The AFM results therefore corroborate the 
previous observations with spectroscopic methods and support the 
strong DNA binding observed with Ru2–R8. Moreover, this 
significant effect of Ru2–R8 on the DNA’s degree of coiling may be 
compared to molecules, i.e. proteins that pack the DNA into 
chromosomes. Hence, such a compound may significantly hamper 
processes requiring the access of proteins to the DNA, for instance 
avoiding the formation of replication fork, and therefore exhibit 
good cytotoxicity.36 
 
Figure 3. AFM images of (a) free relaxed pBR322 DNA (19 µg mL–1) and incubated at 
37 ºC for 24 hours in HEPES with (b) complex ΔΔ–Ru2 (75 µg mL–1), or (c) complex 
Ru2–R8 (75 µg mL–1). 
Cell internalization of the octaarginine metallopeptide and 
cytotoxicity assays. As expected, the introduction of the cationic 
oligoarginine endowed the Ru2–R8 conjugate with effective cell-
internalization properties. Thus, incubation of a 25 µM solution of 
Ru2–R8 for 30 min with Vero cells resulted in a clear and 
homogeneous emission in the red channel within the whole cell 
population (Figure 4, supporting information). At this concentration, 
the luminescence was observed in the form of a punctuated pattern 
in the cytoplasm, which could be related with the formation of 
endosomes involved in endocytosis,37 as well as diffuse emission 
from the cell nuclei (Figure 4).  
 
Figure 4. Monolayers of Vero cells grown in coverslips were incubated in DMEM 
without any additives, in the presence of 25 µM of control compound ΔΔ–Ru2 (top row) 
or Ru2–R8 (bottom row), for 30 minutes at 37 ºC. The figure shows DIC images (left) 
and their correspondent fluorescence images (right). A highly emissive dead cell is seen 
at the bottom-left corner of panel d. 
In addition with improved internalization, the Ru2–R8 complex 
also displayed increased cytotoxic activity, in comparison with the 
unmodified ΛΛ– and ΔΔ–Ru2 complexes. Thus, while a racemic 
mixture of the core Ru2 metallopeptides had an almost negligible 
inhibitory effect on the cellular proliferation of A2780cis ovarian 
carcinoma cells (IC50 ≈ 286 µM), the Ru2–R8 complex exhibited a 
much lower IC50 of 15 µM, comparable to that of cis-diammine-
dichloro-platinum(II) (cisplatin) under the same experimental 
conditions (IC50 ≈ 7 µM). Similar results were obtained for other 
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carcinoma), for which only the octaarginine-tagged Ru2–R8 
metallopeptide had measurable inhibitory effects, which were in all 
cases comparable to those of cisplatin (supporting information). 
Conclusion 
In summary, we report a new class of DNA-binding homochiral 
dinuclear coordination compounds containing a bis-chelating 
peptide backbone, and the first examples of dinuclear ruthenium (II) 
metallopeptides. Detailed studies indicate that these compounds 
bind to DNA by insertion into the DNA with chiral discrimination 
between the ΛΛ– and ΔΔ–Ru2 isomers. Moreover, the synthetic 
versatility and flexibility of solid-phase peptide synthesis (SPPS) 
was exploited to modify the microstructure of the peptidic scaffold, 
thus allowing the straightforward modulation of the DNA-binding 
properties of the resulting complexes, as well as the introduction of 
additional functionalities and properties (i.e. introduction of the 
octaarginine tail for endowing the complexes with cell 
internalization properties). We believe that this innovative approach 
opens new perspectives for programming DNA binding metal 
complexes with novel and useful properties, and can be applied for 
the construction of novel polynuclear polypyridyl Ru(II) 
metallopeptides and related complexes derived from other metal 
ions. 
Experimental Section 
General Methods. All solvents were dry and of synthesis grade. Analytical RP-HPLC 
was performed with an Agilent 1100 series LC/MS with a Luna C18 (250 × 4.60 mm) 
analytical column. Peptides were purified using a Luna C18 (250 × 10 mm) semi-
preparative column. The standard gradient used both for analytical and semi-preparative 
HPLC was 5% to 50% over 30 min (water/acetonitrile, 0.1% TFA). The fractions 
containing the products were freeze-dried, and the identity of the products was 
confirmed by MALDI-TOF and Electrospray Ionization Mass Spectrometry, which was 
performed in an Agilent 1100 Series LC/MSD instrument in positive scan mode. 
Luminescence titration experiments were made with a Jobin-Yvon Fluoromax-3. All 
measurements were made at 20 ºC with the following settings: excitation at 488 nm; 
excitation slit width 3.0 nm, emission slit with 6.0 nm; increment 1.0 nm; integration 
time 1 s. The emission spectra were recorded from 515 to 780 nm. Circular dichroism 
measurements were made with a Jasco J-715 coupled to a thermostated water bath at 20 
ºC. 
Solid phase synthesis of peptidic ligands. C-terminal amide peptides were synthesized 
following standard SPPS protocols on a 0.05 mmol scale using a 0.20 mmol/g Fmoc-
PAL-PEG-PS or 0.45 mmol/g Fmoc-Rink-amide resins. Glycine and arginine were 
coupled, in 10-fold excess (versus mmol of resin load), using HBTU as activating agent. 
The synthetic Fmoc-βAla-5-Bipy-OH amino acid (1) was coupled in 5-fold excess using 
HATU as activating agent. Couplings were conducted for 1 h. Deprotection of the 
temporal Fmoc protecting group was performed with 20% piperidine in DMF for 15 
min. Test cleavages were performed at a 5 mg scale for 2 h with 50 µL CH2Cl2, 25 µL 
H2O, 25 µL TIS, triisopropylsilane, and 900 TFA µL (≈1 mL of cocktail for 100 mg of 
resin). 
Synthesis of homochiral Ru(II) metallopeptides. Once the peptide ligands were 
synthesized, the resin was suspended in 6 mL of DMF in the dark for 15 min. The 
selected chiral precursor Δ– or Λ–[Ru(bpy)2(Py)2]DBT (DBT = dibenzoyl tartrate) was 
added (0.15 mmol, 111 mg), and the resulting mixture was stirred under argon for four 
days at 110 ºC. The resin was filtered, washed with DMF and CH2Cl2 and dried. The 
metallopeptide was cleaved with the TFA cocktail; the resin was filtered and the 
supernatant was concentrated and dissolved in water. Addition of NH4PF6 yielded a red 
precipitate, which was purified by semi-preparative HPLC to give the desired product. 
ΔΔ–Ru2: MALDI-TOF calcd for C70H61N17O5Ru2, 1423.3; found, 1420.4. ESI-MS 
calcd for [M + 2 CF3COO–]2+, 824.5; found, 823.3. ΛΛ–Ru2: MALDI-TOF calcd for 
C70H61N17O5Ru2, 1423.3; found, 1420.4. ESI-MS calcd for [M + 2 CF3COO–]2+, 824.5; 
found, 823.3. ΔΔ–Ru2Gly: MALDI-TOF calcd for C72H64N18O6Ru2, 1480.3; found, 
1480.3. ESI-MS calcd for [M + 2 CF3COO–]2+, 853.1; found, 852.8. ΛΛ–Ru2Gly: 
MALDI-TOF calcd for C72H64N18O6Ru2, 1480.33; found, 1480.3. ESI-MS calcd for [M 
+ 2 CF3COO–]2+, 853.1; found,  852.8. 
Synthesis of racemic Ru(II) metallopeptides. Once the peptide ligands were 
synthesized, the resin was suspended in 6 mL of 1:1 EtOH/DMF in the dark for 15 min. 
The neutral precursor complex Ru(Bpy)2Cl2 was added (0.15 mmol; 71 mg), and the 
resulting mixture was stirred, under argon atmosphere, during 3 days at 70 ºC. The resin 
was then filtered, washed extensively with DMF and CH2Cl2 and dried under vacuum. 
The complex was cleaved from the solid support by treating the resin with the standard 
TFA cocktail. The TFA phase was concentrated by bubbling nitrogen, diluted in water. 
Addition of NH4PF6 to the aqueous solution yields a red precipitate, which was 
dissolved in H2O/CH3CN (3:1) and purified by semi-preparative reverse-phase HPLC to 
give the desired product. Ru2–R8: MALDI-TOF calcd for C118H155N49O13Ru2, 2670.1; 
found = 2669.9 ESI-MS calcd for [M + 5 CF3COO– + 4 H+]3+, 1079.7; found = 1081.2. 
ESI-MS calcd for [M + 6 CF3COO–+5 H+]3+, 1117.7; found = 1117.3, calcd for [M + 7 
CF3COO– + 6 H+]3+, 1155.7; found, 1155.8. Ru2: MALDI-TOF calcd for 
C70H61N17O5Ru2, 1423.31; found, 1420.4. ESI-MS calcd for [M+2 CF3COO–]2+, 824.5; 
found = 823.3. 
Saturation Transfer Difference (STD) NMR studies. NMR samples were prepared in 
500 µL of aqueous buffer containing 10 % (v/v) D2O, 100 mM NaCl and 10 mM 
phosphate buffer at pH 7.5 (not corrected for D2O). All STD NMR experiments were 
performed on a Bruker Avance 600 spectrometer (Billerica, MA, USA) operating at 
600.13 MHz for 1H, equipped with a 5 mm inverse triple resonance probe with Z-only 
gradients. Spectra were processed with TopSpin and MestreNova. A pseudo-2D version 
of the STD NMR pulse sequence was used for the interleaved acquisition of on- and 
off-resonance spectra. Selective saturation of the DNA was performed with a train of 40 
Gauss-shaped pulses of 50 ms length each, separated by a 1 ms delay, leading to a total 
saturation time of 2.04 s. The on-resonance irradiation of the DNA was set at a chemical 
shift of +1.0 and +4.0 ppm. Off-resonance irradiation was applied at –40.0 ppm, where 
no DNA signals were present. Solvent suppression was achieved with the double 
pulsed-field gradient spin-echo (DPFGSE) step. 38  The STD NMR spectra were 
multiplied by an exponential line-broadening function of 3.0 Hz prior to Fourier 
transformation. Saturation transfer was observed in spectra irradiated either at 1.0 or 4.0 
ppm. Peak intensities were larger when saturating at 4.0 ppm (discussed in the text). 
Appropriate blank experiments, in the absence of ctDNA, were performed to test the 
lack of direct saturation to the ligand protons. 
Atomic Force Microscopy (AFM) studies. The AFM images were obtained with a 
Multimode 8 AFM with electronic Nanoscope V scanning probe microscope from 
Bruker AXS, using the PEAK FORCE tapping mode. Commercial Si-tip on Nitride 
lever cantilevers (SNL, Bruker) with force constant of 0.4 N/m were used. The samples 
were deposited on mica disks (PELCO Mica Discs, 9.9 mm diameter; Ted Pella, Inc.), 
and dried before visualization. Solutions of the metal complexes and the buffer were 
prepared just prior to use, and filtered through 0.2 nm FP030/3 filters (Scheicher and 
Schuell, Germany). The samples were prepared in HEPES with relaxed plasmid 
pBR322 DNA (19 µg/µL) and the corresponding metallopeptide (75 × 10–3 µg/mL). All 
samples were incubated for 24 hours at 37 ºC before the AFM studies. 
Cell internalization studies. Semi-confluent monolayers of Vero cells were grown on 
glass coverslips in DMEM (Dulbecco´s modified Eagle Medium) containing 10% of 
FBA (Fetal bovine serum). For the assays, the cells were incubated in DMEM 
containing no FBS or antibiotics, with control compound Ru2 (25 µM) or Ru2–R8 (25 
µM and 5 µM), during 60 or 30 minutes at 37 ºC in a 5% CO2 humidified atmosphere. 
Then, the cells were gently washed 5 times with PBS (Phosphate Buffered Saline), and 
observed under the fluorescence microscope in DMEM without fixation.  
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Custom-fit ruthenium(II) 
metallopeptides: A new twist to 
DNA binding with coordination 
compounds  
 
 A new bipyridine building block has been used for the solid-phase synthesis 
of dinuclear DNA-binding ruthenium(II) metallopeptides which bind to the 
DNA. The potential of the solid-phase peptide synthesis is demonstrated by 
the straightforward synthesis of an octaarginine derivative that shows 
effective cellular internalization and cytotoxicity linked with strong DNA 
interaction. 
 
 
 
